Skip to main
EKSO
EKSO logo

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc is positioned for strong future revenue growth, with projections estimating total revenue of $23 million for 2025, driven by increasing placements of EksoNR devices and the successful navigation of CMS claims for Indego Personal. The company witnessed a promising 21%-24% quarter-over-quarter revenue growth, reaching $4.1 million in Q3 2024, signaling a recovery from previous delays in capital purchases. Additionally, the strategic partnership aimed at expanding the market for Indego and anticipated increased demand for EksoNR in Europe further reinforces the optimistic outlook for long-term value creation.

Bears say

Ekso Bionics Holdings Inc experienced a 2% year-over-year decline in total revenue, falling to $17.9 million in 2024 from a record $18.3 million in 2023, primarily due to reduced enterprise sales influenced by erratic procurement cycles. Although the company saw notable revenue growth in Europe, especially in France, this was insufficient to counterbalance the overall decline in revenue. Additionally, the reported loss on the revaluation of warrant liabilities further underscores the company's financial challenges and contributes to a negative outlook on its stock performance.

EKSO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 5 analysts, EKSO has a Strong Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.